obesity

Drugs like Ozempic and Wegovy were originally developed and described as obesity treatments for patients with medical need, but they are increasingly marketed and used as lifestyle drugs for customers seeking cosmetic or wellness benefits. Commentators note this reframing raises questions about access for people with genuine medical need, pricing, and how the pharmaceutical industry positions these medicines.

Stroke rates among younger adults have nearly doubled, according to a report highlighted by University of Cincinnati researchers. The increase in adults under around 55 marks a shift from stroke's traditional reputation as an older person's illness, and is drawing attention to rising rates of obesity, high blood pressure and diabetes as likely contributing factors. Health experts are urging younger people to monitor blood pressure and adopt healthier lifestyles to reduce their risk.

GLP-1 medications such as Ozempic and Wegovy are being discussed as a new approach to weight loss, moving beyond diet and exercise as the standard advice. Johns Hopkins University is among the institutions weighing in on how these drugs work and what their rise means for obesity treatment. The conversation centers on effectiveness, costs, and how widely these drugs will change care.

India has proposed banning junk food sales in school canteens and within 50 meters of school premises, a measure aimed at curbing rising obesity and diabetes rates among children. The move would restrict children's access to unhealthy snacks and sugary products during and around school hours. Health officials say childhood obesity is a growing concern, and the proposal is drawing attention to how governments regulate food environments for young people.

New research suggests the weight-loss drugs Zepbound and Mounjaro may activate brown fat, a type of body tissue that burns calories to generate heat. If confirmed, the findings could help explain part of how the medications drive weight loss beyond appetite suppression, and point to new ways of boosting metabolism in obesity treatment.

An obesity medicine doctor is addressing the growing trend of microdosing Ozempic, the diabetes drug widely used for weight loss, explaining the safety concerns and potential risks of taking lower-than-standard doses. The doctor notes there are limited situations where a low dose may be appropriate, but warns patients against adjusting medication on their own without medical supervision.

Health experts say weight loss drugs such as GLP-1 medications could offer benefits beyond slimming, potentially helping treat women's reproductive health issues. The suggestion points to a possible new use for a class of medicines already in high demand, and it is drawing attention to how obesity-related treatments might intersect with conditions like polycystic ovary syndrome and fertility problems.

A new study has connected the use of GLP-1 weight-loss and diabetes medications in children with nutritional deficiencies, according to Scripps News, which published an interactive report on the findings. The drugs, widely prescribed to minors amid rising childhood obesity rates, may leave young users short of key nutrients. The findings add to ongoing debate over the safety and supervision of GLP-1 treatment in pediatric patients.

New research suggests that weight regained after dieting may be driven by brain biology rather than simply a lack of willpower, pointing to neural mechanisms that push the body back toward its previous weight after a diet ends. The findings are being discussed as a possible shift in how obesity and dieting failure are understood, with implications for treatment and public attitudes toward weight loss.

A new study suggests that removing ultra-processed food from school menus will be a difficult task. The finding highlights practical obstacles schools face in offering fresher, less processed meals to pupils. The research is drawing attention amid growing public and political concern over ultra-processed food in children's diets and its links to obesity and poor health outcomes.

Eli Lilly has announced the Lilly Change the Course Commitment, a new initiative aimed at narrowing treatment gaps in diabetes and obesity care in low- and middle-income countries. The pharmaceutical company says the programme will focus on expanding access to treatment where need is greatest. Details on funding and specific country plans have not yet been widely reported.

Major food companies in India are urging regulators to reconsider the red colour proposed for warning labels on packaged foods, Reuters reports. The industry argues the red symbol could stigmatise products, while health advocates support strong front-of-pack warnings to combat rising obesity, diabetes and high salt, sugar and fat consumption in the country.

Efforts to ban ultra-processed foods from public schools are running into significant practical obstacles, according to reporting highlighted by News-Medical. Schools face challenges around sourcing affordable alternatives, reworking contracts with food suppliers, and meeting nutrition standards on tight budgets. The debate touches on children's health, obesity prevention, and the feasibility of overhauling cafeteria menus at scale.

New research suggests tirzepatide, the weight-loss and diabetes drug sold as Mounjaro and Zepbound, may activate brown fat, a type of tissue that burns calories to generate heat. If confirmed, the finding could help explain the drug's effectiveness and open new avenues in obesity treatment. Coverage is so far limited, with fitness outlets picking up the claim and experts urging caution until results are published in full.

Novo Nordisk has received approval in Singapore for Wegovy as the first treatment for MASH, a liver disease involving fibrosis. It marks a new indication for the weight-loss drug beyond obesity and diabetes. Attention centres on how semaglutide could expand into treating fatty liver disease globally.

Novo Nordisk is lowering the price of its weight-loss drug Wegovy by 20 percent in Sweden, according to multiple Swedish business and news outlets. The move comes as GLP-1 medicines, once marketed primarily as obesity treatments for patients, are increasingly described in industry coverage as lifestyle drugs competing for customers, intensifying pressure on pricing.

A randomized, double-blind, placebo-controlled trial published in Nature tested safiglipron, an oral small-molecule GLP-1 receptor agonist, in people with early type 2 diabetes. Unlike injectable GLP-1 drugs such as semaglutide, safiglipron is taken as a pill, which could make treatment easier to access. The publication is drawing attention as drugmakers race to develop oral alternatives to popular injectable weight and diabetes medications.

Drugs in the GLP-1 class, such as Ozempic and Wegovy, are being described as changing more than obesity treatment, with new discussion of their effects on mental health. The Atlantic examines how these medications may influence mood, addiction and behavior, suggesting the story of weight loss medicine is expanding into psychiatry and brain science.

Fitness YouTuber MattDoesFitness has published a documentary-style video about spending 48 hours in what he describes as the UK's fattest town, exploring residents' diets, lifestyles and local attitudes to weight and health. The video has drawn large engagement, with hundreds of thousands of likes, and viewers are debating whether the piece sheds light on Britain's obesity crisis or sensationalises it.

Insilico Medicine has nominated ISM1354, a GIPR antagonist designed using its artificial intelligence drug discovery platform, as a preclinical candidate for obesity and related metabolic diseases. The company says the molecule was generated and optimised end-to-end with generative AI tools. It adds to a growing slate of AI-discovered drugs moving toward clinical development, as pharmaceutical firms race to apply machine learning to the booming obesity treatment market.

Viking Therapeutics stock is trading close to the $30 mark as investors weigh the company's prospects in the increasingly crowded obesity drug market. The biotech, developing GLP-1-based treatments, is being watched closely against larger rivals such as Eli Lilly and Novo Nordisk, and market watchers are debating whether its obesity pill candidates can compete.

New reporting indicates that nearly one in six pediatric patients taking GLP-1 medications for weight management show signs of nutritional deficiency. The finding raises concerns among clinicians about monitoring children's diets and micronutrient intake while on these increasingly prescribed obesity drugs. Health experts are urging careful dietary assessment and follow-up care for young patients treated with GLP-1 therapies.

Fitness YouTuber MattDoesFitness has released an investigation into the town with the highest obesity levels in the UK, exploring local eating habits, health services and residents' perspectives on weight. The video has drawn strong engagement, with viewers debating whether the issue reflects personal choices, poverty and food environment, or broader public health policy failures in Britain.

Hong Kong-based biotech Insilico Medicine has nominated ISM1354, a GIPR antagonist designed with its generative AI platform, as a preclinical development candidate for obesity and related metabolic disorders. It is the latest example of artificial intelligence compressing early drug discovery, and observers see it as a test of whether AI-designed molecules can advance into serious clinical pipelines for weight-loss treatment.

The British Nutrition Foundation is calling on the UK government to strengthen food education policy in schools, arguing that better structured teaching about nutrition and food is needed for children. The appeal, reported by food industry outlet New Food, pushes for food education to be given greater priority in the national curriculum.

New reporting flags that GLP-1 medications, increasingly used to treat childhood obesity, may create nutritional risks for children. Because the drugs suppress appetite, young patients could fall short on essential nutrients at a time when their bodies are still developing, raising questions about whether diet supplementation and monitoring should accompany treatment.

Danish drugmaker Novo Nordisk has agreed a deal worth $2.6 billion with China's Hengrui Pharmaceuticals, giving Novo rights to an obesity drug candidate. The agreement underscores fierce competition in the fast-growing weight-loss drug market, where Novo's Wegovy faces mounting rivalry from Eli Lilly and emerging Chinese developers.